We are live on ! Find out more
BDRX icon

Biodexa Pharmaceuticals
BDRX

6 hedge funds and large institutions have $136K invested in Biodexa Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more capital inflows, than outflows

Capital inflows: $147K | Capital outflows: $21K

200% more funds holding

Funds holding: 2 → 6 (+4)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

7.11% less ownership

Funds ownership: 8.15% → 1.04% (-7.1%)

Holders
6
Holders Change
+4
Holders Change %
+200%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
+$41.9K
2
Citadel Advisors
Citadel Advisors
Florida
+$31.4K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$31.4K
4
Two Sigma Securities
Two Sigma Securities
New York
+$21K
5
GSC
Ground Swell Capital
South Carolina
+$10.5K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$10.5K
2
GAMMA Investing
GAMMA Investing
California
-$10.5K

BDRX Hedge Fund Activity: Q2 2024 in Review

6 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q2 2024, worth a combined $136K — up 334% from $31.2K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BDRX positions and 2 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $41.9K. The largest seller was Bank of America, exiting entirely with an estimated $10.5K sold.

  • 6 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q2 2024, up from 2 in Q1 2024.
  • Funds reported $136K of Biodexa Pharmaceuticals stock for Q2 2024, up 334% quarter-over-quarter.
  • 6 funds opened new Biodexa Pharmaceuticals positions in Q2 2024 and 2 closed out, a net change of +4 holders.
  • The largest Biodexa Pharmaceuticals buyer in Q2 2024 was Virtu Financial, an estimated $41.9K added.
  • The largest Biodexa Pharmaceuticals seller in Q2 2024 was Bank of America, an estimated $10.5K sold.

Based on aggregated 13F filings for Q2 2024.